Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Closed 11-04 15:00:00

47.99

+0.43

+0.90%

High48.39	Low47.26	Vol40.66M
Open48.10	D1 Closing47.56	Amplitude2.38%
Mkt Cap306.13B	Tradable Cap306.13B	Total Shares6.38B
T/O1.94B	T/O Rate0.64%	Tradable Shares6.38B
P/B6.99	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":47.99,"timestamp":1730703600000,"preClose":47.56,"halted":0,"volume":40659229,"delay":0,"changeRate":0.009,"floatShares":6379000000,"shares":6379000000,"eps":0.8541,"marketStatus":"Closed","change":0.43,"latestTime":"11-04 15:00:00","open":48.1,"high":48.39,"low":47.26,"amount":1942000000,"amplitude":0.0238,"askPrice":48,"askSize":1686,"bidPrice":47.99,"bidSize":1186,"shortable":0,"etf":0,"ttmEps":0.8541,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1730770200000},"marketStatusCode":5,"adr":0,"adjPreClose":47.56,"symbolType":"stock","openAndCloseTimeList":[[1730683800000,1730691000000],[1730696400000,1730703600000]],"highLimit":52.32,"lowLimit":42.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"isCdr":false,"pbRate":6.99,"roa":"--","peRate":56.1878,"roe":"10.88%","epsLYR":0.68,"committee":0.16189,"marketValue":306128000000,"turnoverRate":0.0064,"status":0,"floatMarketCap":306128000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2478312514","title":"Hengrui Medicine's Unit Gets Nod to Trial Hypertension Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2478312514","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478312514?lang=en_us&edition=fundamental","pubTime":"2024-10-28 14:23","pubTimestamp":1730096617,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine's  unit, Fujian Shengdi Pharmaceutical, will conduct clinical trials on hypertension drug after receiving approval from the Chinese drug administrator, according to a Shanghai Stock Exchange filing on Oct. 25.The pharmaceutical company invested 42.8 million yuan into the research and development of the drug, HRS-9563 injection, the filing said.Shares of the company rose more than 1% in recent trade.Price : 48.70, Change: +0.70, Percent Change: +1.46%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2478647089","title":"Jiangsu Hengrui Medicine Q3 Profit Up 2%, Revenue Climbs 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478647089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478647089?lang=en_us&edition=fundamental","pubTime":"2024-10-25 11:42","pubTimestamp":1729827736,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  posted third-quarter net profit attributable to shareholders of 1.19 billion yuan, up 1.9% from the previous year.The pharmaceutical company's Q3 earnings per share rose 5.6% year over year to 0.19 yuan, according to a Thursday filing with the Shanghai bourse.Revenue climbed 13% to 6.59 billion yuan.Shares of Jiangsu Hengrui Medicine were down 2% in recent trade.Price : 47.89, Change: -0.78, Percent Change: -1.60%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2477045205","title":"Market Chatter: Jiangsu Hengrui Medicine Mulls $2 Billion Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2477045205","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477045205?lang=en_us&edition=fundamental","pubTime":"2024-10-24 17:59","pubTimestamp":1729763965,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  is considering a a secondary listing in Hong Kong that could raise $2 billion, Bloomberg News reported Thursday, citing people familiar with the matter.The Shanghai-listed drug manufacturer is now in talks with advisers regarding the IPO, which could take place as early as 2025, the report said, citing the sources.Price : 48.67, Change: -2.0, Percent Change: -3.99%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1328615791.USD","LU0405327494.USD","BK0196","LU1064130708.USD","BK0239","LU2148510915.USD","LU0405327148.USD","LU2488822045.USD","BK0028","LU1064131003.USD","BK0183","600276","BK0060","BK0012","BK0188"],"gpt_icon":0},{"id":"2477215508","title":"Hengrui Pharmaceuticals  Q3 Net Profit up 1.9% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2477215508","media":"THOMSON REUTERS","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477215508?lang=en_us&edition=fundamental","pubTime":"2024-10-24 16:53","pubTimestamp":1729759991,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nL4N3M0110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Hengrui Pharmaceuticals  Q3 Net Profit up 1.9% Y/Y","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0405327494.USD","LU1328615791.USD","LU2148510915.USD","BK0188","LU2488822045.USD","BK0239","BK0196","LU1064130708.USD","BK0012","LU1064131003.USD","BK0028","BK0183","LU0405327148.USD","600276","BK0060"],"gpt_icon":0},{"id":"2477803786","title":"Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 50.17 Yuan From 48.32 Yuan, Keeps at Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2477803786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477803786?lang=en_us&edition=fundamental","pubTime":"2024-10-22 15:31","pubTimestamp":1729582311,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine (SHA:600276) has an average rating of outperform and price targets ranging from 41.90 yuan to 120 yuan, according to analysts polled by Capital IQ.(MT Newswires covers equity,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMR","600276"],"gpt_icon":0},{"id":"2477776308","title":"Jiangsu Hengrui Likely to Post Stronger 3Q Sales -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2477776308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477776308?lang=en_us&edition=fundamental","pubTime":"2024-10-22 14:39","pubTimestamp":1729579140,"startTime":"0","endTime":"0","summary":"0639 GMT - Jiangsu Hengrui Medicine is expected to post a 15% rise in revenue to 6.7 billion yuan for the third quarter, Nomura analysts say. A stable ramp-up of its innovative drugs likely supported sales, they write in a note. The analysts expect the company's quarterly gross margin to narrow slightly to 86.0% given last year's high base. Third-quarter net profit is tipped at 1.6 billion yuan. Nomura advises investors to keep an eye on the clinical and commercial progress of new drugs in 4Q. It keeps a neutral rating on the stock but raises the target price to CNY50.17 from CNY48.32. Shares are last at CNY50.55. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600276","POST"],"gpt_icon":0},{"id":"2475603786","title":"Jiangsu Hengrui Medicine Gets Approval for Clinical Trial of Heart Failure Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2475603786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475603786?lang=en_us&edition=fundamental","pubTime":"2024-10-16 12:47","pubTimestamp":1729054026,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  secured clinical trial approval for its SHR-6934 injection for the treatment of heart failure, according to a Tuesday filing with the Shanghai bourse.The pharmaceutical company has invested about 8.2 million yuan in SHR-6934 injection-related projects.Jiangsu Hengrui Medicine shares were down 2% in recent trade.Price : 49.42, Change: -1.2, Percent Change: -2.33%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2475387124","title":"Jiangsu Hengrui Medicine Gets Marketing Authorization for T-cell Lymphoma Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2475387124","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475387124?lang=en_us&edition=fundamental","pubTime":"2024-10-14 14:20","pubTimestamp":1728886815,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  secured marketing authorization from China's State Drug Administration for its SHR2554 tablets.The proposed indication for the tablets is for relapsed or refractory peripheral T-cell lymphoma, according to an Oct. 13 filing with the Shanghai bourse.The pharmaceutical company has invested about 150.9 million yuan for the research and development of the SHR2554 tablets.Shares of Jiangsu Hengrui Medicine rose 2% in recent trade.Price : 51.20, Change: +1.0, Percent Change: +1.99%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0405327148.USD","BK0188","BK0196","LU2148510915.USD","BK0060","BK0183","LU2488822045.USD","LU0405327494.USD","BK0239","LU1064131003.USD","BK0028","LU1064130708.USD","LU1328615791.USD","BK0012","600276"],"gpt_icon":0},{"id":"2474057323","title":"US FDA Approves Hengrui Medicine's Abbreviated New Drug Application for Anti-Cancer Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2474057323","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474057323?lang=en_us&edition=fundamental","pubTime":"2024-10-11 16:45","pubTimestamp":1728636350,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration approved Jiangsu Hengrui Medicine's  abbreviated new drug application for its paclitaxel albumin-bound injection, according to a Friday filing with the Shanghai Stock Exchange.The injection is indicated for the treatment of breast and pancreatic cancer, among other cancers, the filing said.Shares closed 5% lower during Friday's trading.Price : 50.20, Change: -2.4, Percent Change: -4.51%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2474293765","title":"Hengrui Medicine Gets Green Light to Trial Bacterial Infection Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2474293765","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474293765?lang=en_us&edition=fundamental","pubTime":"2024-10-10 14:18","pubTimestamp":1728541135,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  will conduct clinical trials on HRS-2183 for injection after receiving approval from China's National Medical Products Administration, according to a Wednesday disclosure on the Shanghai Stock Exchange.The drug is intended for the treatment of bacterial infections.The pharmaceutical company invested 19.4 million yuan into the research and development of the drug, the disclosure said.Shares of the company rose more than 2% in recent trade.Price : 52.87, Change: +1.2, Percent Change: +2.30%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0012","BK0196","BK0183","LU0405327494.USD","LU0405327148.USD","LU1328615791.USD","BK0060","600276","LU1064131003.USD","LU2488822045.USD","LU2148510915.USD","BK0028","LU1064130708.USD","BK0188"],"gpt_icon":0},{"id":"2472259657","title":"CStone Pharmaceuticals Initiates Phase III Clinical Trial for Hepatocellular Carcinoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2472259657","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472259657?lang=en_us&edition=fundamental","pubTime":"2024-10-02 13:49","pubTimestamp":1727848166,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals   has commenced a Phase III clinical trial for its investigational drug CS1002/SHR-8068 in partnership with Jiangsu Hengrui Pharmaceuticals , according to a Wednesday filing with the Hong Kong bourse.The drug is being developed as a potential treatment for advanced hepatocellular carcinoma .CStone and Hengrui signed a strategic partnership and exclusive licensing agreement in November 2021 for the drug.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4006","III","BK1574","BK4134","02616","600276","BK1161","HCC"],"gpt_icon":0},{"id":"2471811610","title":"Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Asthma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2471811610","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471811610?lang=en_us&edition=fundamental","pubTime":"2024-09-30 10:29","pubTimestamp":1727663368,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine (SHA:600276) secured clinical trial approval for its SHR-1905 injection on adolescents aged between 12 and 17 years, according to a Sunday filing with the Shanghai bourse.SHR-1905 is a monoclonal antibody used to treat severe uncontrolled asthma.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2470227283","title":"China Grants Hengrui Medicine Unit Clinical Trial Approval for Brain Imaging Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2470227283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470227283?lang=en_us&edition=fundamental","pubTime":"2024-09-26 12:29","pubTimestamp":1727324964,"startTime":"0","endTime":"0","summary":"Chinese authorities granted Jiangsu Hengrui Medicine  subsidiary Tianjin Hengrui Medicine clinical trial approval for its metazol injection, according to a Thursday filing with the Shanghai Stock Exchange.The drug is used for radioactive diagnosis for brain positron emission tomography imaging, especially for patients with cognitive conditions such as Alzheimer's disease or other conditions, the filing said.Shares rose 1% during recent trade.Price : 44.25, Change: +0.41, Percent Change: +0.94%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","LU0405327494.USD","LU2148510915.USD","LU2488822045.USD","BK0196","LU1064130708.USD","LU0405327148.USD","BK0239","LU1064131003.USD","BK0188","BK0028","LU1328615791.USD","BK0183","600276","BK0012"],"gpt_icon":0},{"id":"2469448191","title":"Jiangsu Hengrui Medicine Units Get China Clinical Trial Approval for Pain Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2469448191","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469448191?lang=en_us&edition=fundamental","pubTime":"2024-09-24 11:38","pubTimestamp":1727149119,"startTime":"0","endTime":"0","summary":"Chinese authorities granted Jiangsu Hengrui Medicine  subsidiaries Shanghai Hengrui Medicine and Shandong Shengdi Pharmaceutical clinical trial approval for HRS-2129 tablets.The drug is indicated for acute and chronic pain, according to a Tuesday filing with the Shanghai Stock Exchange.Price : 42.81, Change: +0.10, Percent Change: +0.23%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2468666978","title":"Hengrui Medicine's Ruilafupu-Î± Injection Receives Marketing Authorization in China; Shares Drop 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468666978","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468666978?lang=en_us&edition=fundamental","pubTime":"2024-09-20 11:45","pubTimestamp":1726803923,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration has accepeted Jiangsu Hengrui Medicine's (SHA:600276) drug marketing authorization application for its Ruilafupu-± injection, according to a Thursday d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064130708.USD","BK0028","BK0196","LU0405327148.USD","LU2488822045.USD","BK0239","BK0012","LU0405327494.USD","BK0060","600276","LU2148510915.USD","BK0188","LU1064131003.USD","LU1328615791.USD","BK0183"],"gpt_icon":0},{"id":"2467741452","title":"China Accepts Hengrui Medicine Unit's Marketing Application for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2467741452","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467741452?lang=en_us&edition=fundamental","pubTime":"2024-09-13 17:54","pubTimestamp":1726221269,"startTime":"0","endTime":"0","summary":"China's medical products administrator accepted Jiangsu Hengrui Medicine  subsidiary Suzhou Shengdia Biopharmaceutical's marketing application for trastuzumab injection, according to a Friday filing with the Shanghai Stock Exchange.The injection is indicated for the treatment of human epidermal growth factor receptor 2-mutated non-small cell lung cancer, the filing said.HER2 is a protein involved in normal cell growth, and some cancers tend to overproduce HER2.Price : 44.77, Change: -0.20, Percent Change: -0.44%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","LU1064130708.USD","LU2488822045.USD","BK0060","LU0405327494.USD","600276","LU2148510915.USD","LU0405327148.USD","LU1064131003.USD","LU1328615791.USD","BK0183","BK0028","BK0188","BK0196","BK0012"],"gpt_icon":0},{"id":"2467741432","title":"China Accepts Hengrui Medicine Unit's Marketing Application for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2467741432","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467741432?lang=en_us&edition=fundamental","pubTime":"2024-09-13 17:54","pubTimestamp":1726221269,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["LU1064131003.USD","LU2488822045.USD","LU0405327494.USD","BK0188","600276","LU0405327148.USD","BK0239","LU2148510915.USD","LU1328615791.USD","BK0196","BK0028","BK0183","BK0060","LU1064130708.USD","BK0012"],"gpt_icon":0},{"id":"2465539549","title":"Hengrui Medicine Gets China Nod for Anti-Hair Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2465539549","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465539549?lang=en_us&edition=fundamental","pubTime":"2024-09-05 20:14","pubTimestamp":1725538498,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted Jiangsu Hengrui Medicine  marketing authorization for its emmacitinib sulfate tablets for severe alopecia areata or hair loss in adults.During clinical trials conducted in June, participants reported good safety and efficacy of the drug, according to a Thursday filing with the Shanghai Stock Exchange.Price : 45.00, Change: +0.49, Percent Change: +1.10%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2463224139","title":"Hengrui Medicine Gets Nod to Trial Three Cancer Treatment Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2463224139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463224139?lang=en_us&edition=fundamental","pubTime":"2024-08-30 11:35","pubTimestamp":1724988923,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  and subsidiary Chengdu Shengdi Pharmaceutical will conduct clinical trials on three drugs after getting the approval of Chinese drug regulator National Medical Products Administration.The drugs to be tested are HRS-5041 tablets, HRS-1167 tablets and SHR2554 tablets, according to a Thursday disclosure on the Shanghai Stock Exchange.The clinical trials will test HRS-5041 tablets in combination with HRS-1167 tablets, SHR2554 tablets, abiraterone acetate tablets , and docetaxel as a treatment for advanced prostate cancer, the pharmaceutical company said.Price : 44.16, Change: -0.16, Percent Change: -0.36%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","LU1064130708.USD","LU0405327148.USD","600276","LU1328615791.USD","BK0012","BK0183","BK0060","BK0188","LU1064131003.USD","BK0239","LU2148510915.USD","BK0196","BK0028","LU0405327494.USD"],"gpt_icon":0},{"id":"2461333173","title":"Jiangsu Hengrui Medicine Fiscal 2024 Profit Up 49%, Operating Income Rises 22%; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461333173","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461333173?lang=en_us&edition=fundamental","pubTime":"2024-08-22 10:14","pubTimestamp":1724292859,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  posted first-half net profit attributable to shareholders of 3.43 billion yuan, or 0.54 yuan per share, up 49% from 2.31 billion yuan, or 0.36 yuan per share, the previous year.The pharmaceutical company's operating income rose 22% year over year to 13.60 billion yuan from 11.17 billion yuan, according to a filing with the Shanghai bourse.Shares gained over 3% in recent trade.Price : 43.97, Change: +1.7, Percent Change: +3.92%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":-0.0824},{"period":"3month","weight":0.1184},{"period":"6month","weight":0.039},{"period":"1year","weight":0.0151},{"period":"ytd","weight":0.0663}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"15265股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0079},{"period":"3month","weight":0.1545},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.0922},{"period":"ytd","weight":0.1127}],"survey":"　　江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售，主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内，公司严格遵守环境保护法，依法持证排污，并按时缴纳环境保护税，环保信用评价等级为“绿色”，为“环保示范性企事业单位”及江苏省“绿色发展领军企业”，获得连云港经济技术开发区企业“环境保护质量奖”荣誉。","serverTime":1730756009505,"listedPrice":11.98,"stockholders":"417865人(较上一季度减少8.23%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction